O	0	10	Prevention
O	11	13	of
B-condition	14	25	doxorubicin
I-condition	25	26	-
I-condition	26	33	induced
I-condition	34	48	Cardiotoxicity
O	49	51	by
O	52	67	pharmacological
O	68	71	non
O	71	72	-
O	72	79	hypoxic
O	80	90	myocardial
O	91	106	preconditioning
O	107	112	based
O	113	115	on
B-intervention	116	131	Docosahexaenoic
I-intervention	132	136	Acid
I-intervention	137	138	(
I-intervention	138	141	DHA
I-intervention	141	142	)
I-intervention	143	146	and
I-intervention	147	157	carvedilol
O	158	164	direct
O	165	176	antioxidant
O	177	184	effects
O	184	185	:
O	186	191	study
O	192	200	protocol
O	201	204	for
O	205	206	a
O	207	212	pilot
O	212	213	,
O	214	224	randomized
O	224	225	,
O	226	232	double
O	232	233	-
O	233	238	blind
O	238	239	,
O	240	250	controlled
O	251	256	trial
O	257	258	(
O	258	264	CarDHA
O	265	270	trial
O	270	271	)
O	271	272	.

O	273	286	Anthracycline
O	286	287	-
O	287	294	induced
O	295	309	cardiotoxicity
O	310	311	(
O	311	314	AIC
O	314	315	)
O	315	316	,
O	317	318	a
O	319	328	condition
O	329	339	associated
O	340	344	with
O	345	353	multiple
O	354	364	mechanisms
O	365	367	of
O	368	374	damage
O	374	375	,
O	376	385	including
O	386	395	oxidative
O	396	402	stress
O	402	403	,
O	404	407	has
O	408	412	been
O	413	423	associated
O	424	428	with
O	429	433	poor
O	434	442	clinical
O	443	451	outcomes
O	451	452	.

O	453	463	Carvedilol
O	463	464	,
O	465	466	a
O	467	468	β
O	468	469	-
O	469	476	blocker
O	477	481	with
O	482	488	unique
O	489	500	antioxidant
O	501	511	properties
O	511	512	,
O	513	520	emerged
O	521	523	as
O	524	525	a
O	526	534	strategy
O	535	537	to
O	538	545	prevent
O	546	549	AIC
O	549	550	,
O	551	554	but
O	555	561	recent
O	562	568	trials
O	569	577	question
O	578	581	its
O	582	595	effectiveness
O	595	596	.

O	597	601	Some
O	602	610	evidence
O	611	619	suggests
O	620	624	that
O	625	628	the
O	629	640	antioxidant
O	640	641	,
O	642	645	not
O	646	649	the
O	650	651	β
O	651	652	-
O	652	659	blocker
O	660	666	effect
O	666	667	,
O	668	673	could
O	674	681	prevent
O	682	689	related
O	690	704	cardiotoxicity
O	704	705	.

O	706	713	However
O	713	714	,
O	715	725	carvedilol
O	725	726	'
O	726	727	s
O	728	739	antioxidant
O	740	747	effects
O	748	751	are
O	752	760	probably
O	761	764	not
O	765	771	enough
O	772	774	to
O	775	782	prevent
O	783	797	cardiotoxicity
O	798	812	manifestations
O	813	815	in
O	816	823	certain
O	824	829	cases
O	829	830	.

O	831	833	We
O	834	845	hypothesize
O	846	850	that
O	851	857	breast
O	858	864	cancer
O	865	873	patients
O	874	880	taking
O	881	891	carvedilol
O	892	894	as
O	895	899	well
O	900	902	as
O	903	904	a
O	905	908	non
O	908	909	-
O	909	916	hypoxic
O	917	927	myocardial
O	928	943	preconditioning
O	944	949	based
O	950	952	on
O	953	968	docosahexaenoic
O	969	973	acid
O	974	975	(
O	975	978	DHA
O	978	979	)
O	979	980	,
O	981	983	an
O	984	992	enhancer
O	993	995	of
O	996	1003	cardiac
O	1004	1014	endogenous
O	1015	1026	antioxidant
O	1027	1035	capacity
O	1035	1036	,
O	1037	1041	will
O	1042	1049	develop
O	1050	1054	less
O	1055	1066	subclinical
O	1067	1081	cardiotoxicity
O	1082	1096	manifestations
O	1097	1101	than
O	1102	1110	patients
O	1111	1121	randomized
O	1122	1124	to
B-control	1125	1131	double
I-control	1132	1139	placebo
O	1139	1140	.

O	1141	1143	We
O	1144	1152	designed
O	1153	1154	a
O	1155	1160	pilot
O	1160	1161	,
O	1162	1172	randomized
O	1173	1183	controlled
O	1183	1184	,
O	1185	1188	two
O	1188	1189	-
O	1189	1192	arm
O	1193	1201	clinical
O	1202	1207	trial
O	1208	1212	with
B-total-participants	1213	1215	32
O	1216	1224	patients
O	1225	1227	to
O	1228	1236	evaluate
O	1237	1240	the
O	1241	1248	effects
O	1249	1251	of
O	1252	1255	non
O	1255	1256	-
O	1256	1263	hypoxic
O	1264	1271	cardiac
O	1272	1287	preconditioning
O	1288	1289	(
O	1289	1292	DHA
O	1292	1293	)
O	1294	1298	plus
O	1299	1309	carvedilol
O	1310	1312	on
O	1313	1324	subclinical
O	1325	1339	cardiotoxicity
O	1340	1342	in
B-eligibility	1343	1349	breast
I-eligibility	1350	1356	cancer
I-eligibility	1357	1365	patients
I-eligibility	1366	1376	undergoing
I-eligibility	1377	1390	anthracycline
I-eligibility	1391	1400	treatment
O	1400	1401	.

O	1402	1405	The
O	1406	1411	trial
O	1412	1420	includes
O	1421	1425	four
O	1426	1428	co
O	1428	1429	-
O	1429	1436	primary
O	1437	1446	endpoints
O	1446	1447	:
B-outcome-Measure	1448	1455	changes
I-outcome-Measure	1456	1458	in
I-outcome-Measure	1459	1463	left
I-outcome-Measure	1464	1475	ventricular
I-outcome-Measure	1476	1484	ejection
I-outcome-Measure	1485	1493	fraction
I-outcome-Measure	1494	1495	(
I-outcome-Measure	1495	1499	LVEF
I-outcome-Measure	1499	1500	)
O	1501	1511	determined
O	1512	1514	by
O	1515	1522	cardiac
O	1523	1531	magnetic
O	1532	1541	resonance
O	1542	1543	(
O	1543	1546	CMR
O	1546	1547	)
O	1547	1548	;
B-outcome-Measure	1549	1556	changes
I-outcome-Measure	1557	1559	in
I-outcome-Measure	1560	1566	global
I-outcome-Measure	1567	1579	longitudinal
I-outcome-Measure	1580	1586	strain
I-outcome-Measure	1587	1588	(
I-outcome-Measure	1588	1591	GLS
I-outcome-Measure	1591	1592	)
O	1593	1603	determined
O	1604	1606	by
O	1607	1610	two
O	1610	1611	-
O	1611	1622	dimensional
O	1623	1639	echocardiography
O	1640	1641	(
O	1641	1645	ECHO
O	1645	1646	)
O	1646	1647	;
B-outcome-Measure	1648	1657	elevation
I-outcome-Measure	1658	1660	in
I-outcome-Measure	1661	1666	serum
I-outcome-Measure	1667	1677	biomarkers
I-outcome-Measure	1678	1679	(
I-outcome-Measure	1679	1681	hs
I-outcome-Measure	1681	1682	-
I-outcome-Measure	1682	1686	cTnT
I-outcome-Measure	1687	1690	and
I-outcome-Measure	1691	1693	NT
I-outcome-Measure	1693	1694	-
I-outcome-Measure	1694	1700	ProBNP
I-outcome-Measure	1700	1701	)
O	1701	1702	;
O	1703	1706	and
B-outcome-Measure	1707	1710	one
I-outcome-Measure	1711	1731	electrocardiographic
I-outcome-Measure	1732	1740	variable
I-outcome-Measure	1741	1742	(
I-outcome-Measure	1742	1745	QTc
I-outcome-Measure	1746	1754	interval
I-outcome-Measure	1754	1755	)
O	1755	1756	.

O	1757	1766	Secondary
O	1767	1776	endpoints
O	1777	1784	include
O	1785	1790	other
O	1791	1798	imaging
O	1798	1799	,
B-outcome-Measure	1800	1810	biomarkers
O	1811	1814	and
O	1815	1818	the
B-outcome-Measure	1819	1829	occurrence
I-outcome-Measure	1830	1832	of
I-outcome-Measure	1833	1838	major
I-outcome-Measure	1839	1846	adverse
I-outcome-Measure	1847	1854	cardiac
I-outcome-Measure	1855	1861	events
O	1862	1868	during
O	1869	1875	follow
O	1875	1876	-
O	1876	1878	up
O	1878	1879	.

O	1880	1883	The
O	1884	1894	enrollment
O	1895	1898	and
O	1899	1905	follow
O	1905	1906	-
O	1906	1908	up
O	1909	1912	for
O	1913	1921	clinical
O	1922	1930	outcomes
O	1931	1933	is
O	1934	1941	ongoing
O	1941	1942	.

O	1943	1945	We
O	1946	1952	expect
O	1953	1954	a
O	1955	1960	group
O	1961	1963	of
O	1964	1977	anthracycline
O	1977	1978	-
O	1978	1985	treated
O	1986	1992	breast
O	1993	1999	cancer
O	2000	2008	patients
O	2009	2016	exposed
O	2017	2019	to
O	2020	2030	carvedilol
O	2031	2034	and
O	2035	2038	non
O	2038	2039	-
O	2039	2046	hypoxic
O	2047	2057	myocardial
O	2058	2073	preconditioning
O	2074	2078	with
O	2079	2082	DHA
O	2083	2085	to
O	2086	2090	show
O	2091	2095	less
O	2096	2107	subclinical
O	2108	2122	cardiotoxicity
O	2123	2137	manifestations
O	2138	2142	than
O	2143	2144	a
O	2145	2155	comparable
O	2156	2161	group
O	2162	2169	exposed
O	2170	2172	to
O	2173	2180	placebo
O	2180	2181	.

O	2182	2188	ISRCTN
O	2189	2197	registry
O	2197	2198	,
O	2199	2201	ID
O	2201	2202	:
O	2203	2217	ISRCTN69560410
O	2217	2218	.

O	2219	2229	Registered
O	2230	2232	on
O	2233	2234	8
O	2235	2239	June
O	2240	2244	2016
O	2244	2245	.
